Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03291223 · ClinicalTrials.gov registry record
Gaucher Disease Outcome Survey (GOS)
A clinical trial of Gaucher Disease, sponsored by Shire.
- Recruiting
- Registry status
- 1,257
- Enrollment target
- 1
- Study location
NCT03291223: Recruiting study of Gaucher Disease, sponsored by Shire.
NCT03291223 is a study of Gaucher Disease that is actively recruiting participants, run by Shire. The registered enrollment target is 1,257 participants, above the 962-participant average among 13 other Gaucher Disease trials with a reported enrollment target (31% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03291223, a study of Gaucher Disease, is actively recruiting participants, sponsored by Shire.
- RECRUITING
- Registry status
- 1,257 participants
- Enrollment target
- 1
- Study location
Study Summary
The Gaucher Outcomes Survey (GOS) is an ongoing observational, international, multi-center, long-term Registry of Patients with Gaucher Disease irrespective of their treatment status or type of treatment received. No experimental intervention is involved. Patients undergo clinical assessments and receive care as determined by the patients' treating physician. The objectives of the registry include to evaluate the safety and long-term effectiveness of velaglucerase alfa, to characterize patients receiving velaglucerase alfa or other Gaucher Disease-specific treatments, to gain a better understanding of the natural history of GD and to serve as a database for evidence-based management of Gaucher Disease over time in real-life clinical practice.
Primary Outcome
Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) that either commenced or worsened following the first dose of VPRIV.
Conditions Studied
Study Locations (1)
Massachusetts
- Central Contact - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,257 participants |
| Start Date | 2010-07-27 |
| Est. Completion | 2026-09-30 |
What NCT03291223 shows while recruiting
NCT03291223 is an observational study that tracks outcomes without assigning an intervention. Its 1,257 participants enrollment target places it among the larger protocols in the corpus, above the 962-participant average among 13 other Gaucher Disease trials with a reported enrollment target (31% higher).
The record links to 1 condition, with Gaucher Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03291223 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03291223 about?
NCT03291223 is a clinical study titled "Gaucher Disease Outcome Survey (GOS)". The Gaucher Outcomes Survey (GOS) is an ongoing observational, international, multi-center, long-term Registry of Patients with Gaucher Disease irrespective of their treatment status or type of treatment received. No experimental intervention is involved. Patients undergo clinical assessments and re...
What is the current status of trial NCT03291223?
This trial is currently recruiting. The enrollment target is 1,257 participants. The study started on 2010-07-27. Estimated completion is 2026-09-30.
What conditions does trial NCT03291223 study?
This clinical trial studies the following conditions: Gaucher Disease.
Who is sponsoring clinical trial NCT03291223?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03291223 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gaucher Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03291223's enrollment target sits among peer trials
1,257 2nd of 13 the highest of 13 other Gaucher Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gaucher Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease
RECRUITING
-
A Long-term Follow-up Study of Gaucher Disease
RECRUITING
-
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
RECRUITING
-
The GBA Multimodal Study in Parkinson's Disease
RECRUITING
-
Drug Discovery for Parkinson's With Mutations in the GBA Gene
RECRUITING
-
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI